Belgian biopharmaceutical company Cardio3 Biosciences, which is backed by a consortium of venture capital firms, has announced that it is considering listing new shares in an IPO.
The company, which raised €19m last month from existing investors in the form of €7m in fresh equity and €12m as a conversion of convertible loans, hopes to raise new funds through an IPO on NYSE...
Launched with a €100m target, the fund hit its final close after 19 months on the road
Deal marks the fourth investment completed with the €180m Vendis Capital II fund
Princi joins Idinvest from French asset manager Amundi, where he was deputy general counsel
GP has fully exited its portfolio company after a 10-year holding period